MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$137,999K
Proceeds from exercise of
stock options
$1,275K
Net cash provided by
financing activities
$129,609K
Canceled cashflow
$9,665K
Net change in cash,
cash equivalents and...
-$12,840K
Canceled cashflow
$129,609K
Proceeds from sale or
maturities of marketable...
$101,276K
Share-based compensation
$8,368K
Prepaid expenses and
other current assets
-$5,116K
Accrued expenses
$5,096K
Rou asset
amortization
$1,196K
Depreciation and
amortization
$276K
Issuance costs from
issuance of common stock
$8,638K
Taxes paid related to
net shares...
$1,027K
Net cash (used in)
provided by investing...
-$93,306K
Canceled cashflow
$101,276K
Net cash used in
operating activities
-$49,143K
Canceled cashflow
$20,052K
Purchases of marketable
securities
$194,557K
Purchase of property and
equipment
$25K
Net loss
-$66,489K
Amortization of premium and
discount on marketable...
-$1,673K
Accounts payable
-$664K
Operating lease liability
-$369K
Back
Back
Cash Flow
source: myfinsight.com
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)